Reply to Kevin Lu's letter to the editor re: Arun A. Azad, Bernhard J. Eigl, Raya Leibowitz-Amit, et al. outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol 2015;67:441-7

Eur Urol. 2015 Sep;68(3):e57-8. doi: 10.1016/j.eururo.2015.03.042. Epub 2015 Apr 8.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Abiraterone Acetate / therapeutic use*
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Cytochrome P-450 Enzyme Inhibitors / therapeutic use*
  • Health Status*
  • Humans
  • Male
  • Neoplasms, Hormone-Dependent / drug therapy*
  • Prostatic Neoplasms, Castration-Resistant / drug therapy*
  • Steroid Synthesis Inhibitors / therapeutic use*

Substances

  • Antineoplastic Agents, Hormonal
  • Cytochrome P-450 Enzyme Inhibitors
  • Steroid Synthesis Inhibitors
  • Abiraterone Acetate